Antiplatelet Agents
PreclinicalSmall molecule
Antiplatelet Agents is one of 103 small molecule programs targeting Stroke. It is currently in Preclinical.
4
Indications
11
Total Trials
3
Active Trials
102
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
147 competitors in Stroke
#DrugCompanyPhaseTrials
1Zometa
PfizerPreclinical
Savella
AbbViePreclinical
Proamatine
TakedaPreclinical
Repatha
AmgenPreclinical
Alka-Seltzer
AAbbott
Preclinical
Periactin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Zantac 150
CChattem
Preclinical
Haldol
DDePuy Orthopaedics
Preclinical
Anticoagulants
SanofiPreclinical
Anticoagulant
BayerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Coronary Artery Ectasia1 trial
Coronary Artery Ectasia in Elective Coronary Angiography : Predictors, Outcomes and Management
Completed·—·N/A·NCT03896321·79 enrolled
Large Vessel Occlusion1 trial
6 more indications
Endothelial Function1 trial
Intracerebral Hemorrhage1 trial
Early-Start Antiplatelet Treatment After Neurosurgery in Patients With Spontaneous Intracerebral Hemorrhage
Completed·—·N/A·NCT04820972·269 enrolled
Ventricular Thrombus1 trial
Stroke, Acute1 trial
A Multi-centre, Prospective, Randomized, Open-label, Blinded Endpoint (PROBE) Controlled Trial Comparing Cervical Internal Carotid Artery Stenting to no Stenting During Thrombectomy for Tandem Occlusion Stroke
Recruiting·CCentre hospitalier de l'Université de Montréal (CHUM)·Preclinical·NCT04261478·458 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Antiplatelet Agents. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details